Elite Journal of Nursing and Health Sciences. Volume 2 Issue 7(2024), Pp. 1-20 https://epjournals.com/journals/EJNHS

Malaria and Antenatal Care: Bridging Gaps for Improved Pregnancy Outcomes

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[2]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Malaria during pregnancy poses significant risks to both maternal and fetal health, contributing to adverse outcomes such as low birth weight, preterm birth, and stillbirth. Antenatal care (ANC) is crucial in addressing these risks, yet gaps remain in the prevention, diagnosis, and treatment of malaria in pregnant women. This review examines the intersection of malaria and ANC, highlighting current challenges and proposing strategies to bridge these gaps. Key interventions include the implementation of intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine, the use of insecticide-treated nets (ITNs), prompt diagnosis and treatment of malaria, and comprehensive maternal education. The review underscores the importance of effective ANC in managing malaria and improving pregnancy outcomes. IPTp significantly reduces the incidence of maternal malaria and its associated complications, while ITNs provide essential protection against malaria transmission. Prompt diagnosis and treatment of malaria with appropriate antimalarial therapies are critical in preventing severe outcomes and ensuring the health of both the mother and fetus. Health education plays a vital role in enhancing adherence to preventive measures and facilitating early intervention. Addressing the gaps in malaria prevention and management through ANC requires a multifaceted approach. Expanding access to and adherence to IPTp and ITNs, improving diagnostic and treatment practices, and integrating health education into ANC services are essential for reducing the impact of malaria on pregnancy outcomes. By implementing these strategies effectively and fostering continued research, healthcare systems can improve maternal and fetal health and reduce the burden of malaria in pregnancy.

Keywords: *Malaria, antenatal care, pregnancy outcomes, intermittent preventive treatment, insecticide-treated nets, maternal health, fetal health*

Citation: Obeagu EI, Obeagu GU. Malaria and Antenatal Care: Bridging Gaps for Improved Pregnancy Outcomes**.** Elite Journal of Nursing and Health Science, 2024; 2(7):1-20

Introduction

Malaria, caused by *Plasmodium* parasites and transmitted through Anopheles mosquitoes, is a major global health concern, particularly in tropical and subtropical regions. Among its various impacts, malaria during pregnancy poses severe risks to both maternal and fetal health. Pregnant women are particularly vulnerable due to physiological changes that alter immune responses and increase susceptibility to infection. Consequently, malaria can lead to a range of adverse outcomes, including low birth weight, preterm birth, stillbirth, and maternal mortality. Addressing malaria effectively requires a comprehensive approach integrated into antenatal care (ANC) services. Antennatal care is a critical component of maternal healthcare aimed at ensuring the health of both the mother and the developing fetus. ANC services provide essential monitoring, preventive measures, and therapeutic interventions to manage potential complications during pregnancy. In malaria-endemic areas, effective ANC includes strategies to prevent, diagnose, and treat malaria, thus mitigating its adverse effects on pregnancy outcomes. However, gaps in the implementation and effectiveness of these strategies can undermine the quality of care and result in preventable complications. One of the primary challenges in managing malaria during pregnancy is ensuring the effective use of preventive measures. Intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP) has been shown to significantly reduce malaria incidence and related complications when administered at scheduled intervals. Despite its proven benefits, adherence to IPTp guidelines can be inconsistent due to factors such as inadequate healthcare infrastructure, limited access to medications, and varying levels of patient compliance. Addressing these gaps is crucial for improving malaria prevention during pregnancy.[1-5]

Insecticide-treated nets (ITNs) are another key preventive measure against malaria, providing a physical barrier between pregnant women and malaria-carrying mosquitoes. ITNs have been shown to reduce malaria incidence and improve pregnancy outcomes by decreasing mosquito bites and transmission rates. However, challenges such as limited access to ITNs, inadequate usage, and the need for regular re-impregnation of nets can affect their effectiveness. Ensuring widespread distribution and proper use of ITNs is essential for enhancing malaria prevention efforts. Prompt diagnosis and treatment of malaria are critical for preventing severe outcomes and ensuring effective management. Rapid diagnostic tests (RDTs) and microscopy are essential tools for accurate malaria diagnosis. Artemisinin-based combination therapies (ACTs) are the recommended treatment for malaria during pregnancy. However, delays in diagnosis, inadequate treatment practices, and challenges in accessing quality healthcare services can lead to suboptimal management of malaria, resulting in increased morbidity and mortality. Health education is an integral component of antenatal care, playing a significant role in improving malaria prevention and management. Educating pregnant women about the importance of IPTp, proper use of ITNs, and early recognition of malaria symptoms can enhance adherence to preventive measures and facilitate timely treatment. Effective health education programs should be integrated into ANC services to empower women with the knowledge and resources needed to protect their health and that of their unborn children.[6-10]

Epidemiology

Malaria remains a major global health challenge, with the highest burden concentrated in tropical and subtropical regions. According to the World Health Organization (WHO), malaria is endemic in over 90 countries, primarily in sub-Saharan Africa, parts of South Asia, Southeast Asia, and the Pacific Islands. Pregnant women are particularly vulnerable to malaria, and the disease disproportionately affects these populations in malaria-endemic regions. The World Malaria Report 2023 indicates that there were approximately 247 million cases of malaria globally, with sub-Saharan Africa accounting for the vast majority of cases and deaths. Pregnant women are at an increased risk of severe malaria due to changes in immunity and physiological adaptations during pregnancy. The disease can be especially severe in women who are experiencing their first pregnancy or who have a low immunity to malaria. In malaria-endemic areas, up to 25% of pregnant women may experience malaria infection. The incidence and prevalence of malaria in pregnancy can vary based on geographical factors, seasonal variations, and the effectiveness of malaria control measures in place. The burden of malaria in pregnancy differs significantly across regions. In sub-Saharan Africa, where malaria transmission is high and continuous, pregnant women face a high risk of malaria-related complications. In contrast, regions with lower transmission rates, such as parts of South Asia and Southeast Asia, experience a lower incidence of malaria in pregnancy. Regional variations are influenced by factors such as the intensity of malaria transmission, climate, access to healthcare, and the availability of preventive and therapeutic interventions.[11-15]

Socioeconomic status and environmental factors play a crucial role in malaria epidemiology. Poor living conditions, limited access to healthcare, and inadequate housing can increase the risk of malaria transmission. Additionally, environmental factors such as stagnant water and inadequate sanitation contribute to mosquito breeding sites, further exacerbating the risk of malaria. In malaria-endemic areas, low socioeconomic status often correlates with limited access to preventive measures like insecticide-treated nets (ITNs) and intermittent preventive treatment (IPTp), which can increase vulnerability to the disease. Recent trends in malaria epidemiology show a mixed picture. While there have been significant advancements in malaria control, such as increased coverage of ITNs and IPTp, and improvements in diagnostics and treatment, progress has been uneven. In some regions, malaria transmission has decreased substantially, while in others, progress has stalled or reversed. Factors such as drug resistance, insecticide resistance, and disruptions to malaria control programs due to conflict or health system weaknesses pose ongoing challenges to malaria control efforts. The implementation of malaria control interventions has significantly impacted the epidemiology of malaria. Strategies such as the distribution of ITNs, indoor residual spraying (IRS), and the use of IPTp have contributed to reductions in malaria prevalence and morbidity. However, the effectiveness of these interventions can be affected by challenges such as insecticide resistance, suboptimal coverage, and gaps in healthcare infrastructure. Continued efforts to enhance and sustain malaria control measures are essential for maintaining progress and reducing the burden of malaria in pregnancy. Emerging trends in malaria epidemiology include the impact of climate change on malaria transmission patterns and the potential for new malaria control technologies. Climate change can influence mosquito breeding sites, transmission dynamics, and the geographic distribution of malaria. Research into novel malaria vaccines and new antimalarial drugs holds promise for improving malaria control and

reducing the burden of the disease. Ongoing monitoring and adaptation to these emerging trends are crucial for effective malaria management and control.[16-20]

Pathophysiology

The pathophysiology of malaria during pregnancy involves complex interactions between the malaria parasites, the maternal immune system, and the placenta. Understanding these interactions is crucial for managing and mitigating the adverse effects of malaria on maternal and fetal health. Malaria is caused by protozoan parasites of the genus *Plasmodium*, with *Plasmodium falciparum* being the most common and severe species affecting pregnant women. During pregnancy, *P. falciparum* can sequester in the placenta, where it adheres to placental endothelial cells through a process known as cytoadherence. This sequestration occurs due to the expression of specific adhesive molecules on the surface of infected red blood cells, such as VAR2CSA, which bind to chondroitin sulfate A (CSA) on the placental tissue. This adhesion disrupts normal placental function and can lead to a range of complications. The adhesion of malaria parasites to the placenta causes localized inflammation and interferes with the placental blood supply. This inflammation is mediated by the activation of the maternal immune system and the release of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and interleukins. The resultant placental inflammation, or placentitis, leads to impaired nutrient and oxygen transfer from the mother to the fetus. Consequently, the fetus may experience intrauterine growth restriction (IUGR) and low birth weight. Pregnant women exhibit altered immune responses to malaria due to physiological changes that occur during pregnancy. The maternal immune system undergoes modulation to prevent the rejection of the fetus, which can also impact the ability to control malaria infections. The reduced immune response during pregnancy can lead to higher parasite loads and more severe manifestations of malaria. Additionally, pregnancy-specific immune changes may make women more susceptible to the severe forms of malaria, such as cerebral malaria and severe anemia.[21-25]

Anemia is a common complication of malaria during pregnancy and can result from both the destruction of infected red blood cells by the parasites and the body's response to the infection. Malaria-induced anemia can be exacerbated by the increased demand for iron during pregnancy and reduced iron absorption due to inflammation. Maternal anemia contributes to fatigue, weakness, and an increased risk of complications during delivery. It also negatively impacts fetal health, as reduced maternal hemoglobin levels can impair oxygen delivery to the fetus. The pathophysiological effects of malaria on pregnancy lead to several adverse outcomes. Intrauterine growth restriction (IUGR) occurs due to compromised placental function and reduced nutrient and oxygen supply to the fetus. Low birth weight is a common result of IUGR and is associated with increased neonatal morbidity and mortality. Preterm birth, another possible outcome, results from the inflammatory response and increased risk of preterm labor. Severe cases of malaria can also lead to stillbirth or neonatal death. Malaria during pregnancy can interact with other maternal conditions, exacerbating the risk of adverse outcomes. For instance, women with pre-existing conditions such as diabetes or hypertension may experience worsened outcomes when affected by malaria. The interaction between malaria and these conditions can complicate the management of both the infection and the co-existing conditions, leading to increased risks for both the mother

and the fetus. The inflammatory response triggered by placental malaria is a key factor in its pathophysiology. The activation of immune cells in the placenta leads to the release of inflammatory mediators, which contribute to tissue damage and impaired placental function. This inflammation can also affect the maternal circulation, leading to systemic effects such as fever, which further complicates pregnancy and can increase the risk of preterm labor and other complications. The direct impact of malaria on fetal development includes the risk of neurological and developmental impairments. Severe malaria and its associated complications can influence brain development and cognitive function in neonates. Additionally, low birth weight and preterm birth increase the likelihood of neonatal complications, including respiratory distress and susceptibility to infections. Children born to mothers who had malaria during pregnancy may face long-term health challenges. The early-life effects of malaria can include increased vulnerability to infections, developmental delays, and poor growth outcomes. These long-term consequences underscore the importance of effective malaria management and prevention during pregnancy to improve the overall health and development of children.[26-35]

Effects on Maternal Health

One of the most common and serious consequences of malaria during pregnancy is maternal anemia. Malaria-induced anemia results from the destruction of infected and uninfected red blood cells by the parasite and the body's inflammatory response to the infection. The anemia exacerbates the increased demand for iron and nutrients during pregnancy, leading to fatigue, weakness, and impaired physical functioning. Severe anemia can also increase the risk of complications during childbirth, such as postpartum hemorrhage and inadequate oxygen supply to both the mother and the fetus. Malaria during pregnancy can lead to various forms of maternal morbidity. The disease may manifest as mild febrile illness or escalate to severe forms, including cerebral malaria, which presents with neurological symptoms and can lead to coma and death if untreated. Severe malaria can cause systemic complications such as acute respiratory distress syndrome (ARDS), renal failure, and liver dysfunction. Maternal morbidity is associated with increased healthcare utilization, prolonged hospital stays, and long-term health consequences. Pregnant women with malaria are at an increased risk of developing pre-eclampsia, a condition characterized by high blood pressure and proteinuria. The inflammatory response triggered by malaria and its effects on placental function contribute to the development of pre-eclampsia. This condition can lead to severe complications, including eclampsia (seizures) and organ failure, which pose significant risks to both the mother and the fetus. Managing pre-eclampsia in the context of malaria requires careful monitoring and medical intervention. Maternal malaria can increase the risk of hemorrhage during and after childbirth. The disease's impact on blood clotting mechanisms, combined with anemia, heightens the risk of postpartum hemorrhage, which is a leading cause of maternal mortality. Malaria-related inflammation and infection can also contribute to placental abruption (the premature separation of the placenta from the uterine wall), which further increases the risk of bleeding and complicates delivery.[36-45]

Pregnancy induces immunological changes that modulate the maternal immune response to ensure tolerance of the fetus. These changes can also impair the ability to effectively combat malaria infections. Malaria during pregnancy can lead to an exacerbated immune response, resulting in

increased susceptibility to other infections and complications. The overall compromise of immune function can impact the mother's health and increase the likelihood of severe disease outcomes. Women with malaria during pregnancy are more susceptible to other infections due to their compromised immune system. The increased vulnerability to co-infections can complicate the clinical management of malaria and exacerbate maternal health issues. These additional infections can lead to further health deterioration, increased maternal morbidity, and prolonged recovery periods. The physical and psychological stress of dealing with malaria during pregnancy can impact mental health. Women experiencing severe malaria may face anxiety, depression, and stress related to their health and the potential outcomes for their pregnancy. Addressing mental health concerns is an essential component of comprehensive maternal care, as psychological well-being significantly influences overall health and recovery. The long-term health effects of malaria during pregnancy can be significant. Women who have experienced severe malaria or its complications may have lasting health issues such as chronic anemia or cardiovascular problems. The long-term impacts underscore the importance of effective management and follow-up care to address and mitigate any enduring health consequences. The health effects of malaria during pregnancy can have broader socioeconomic implications. Women experiencing malaria may face increased healthcare costs, reduced productivity, and potential long-term health challenges that impact their ability to work and care for their families. Addressing malaria effectively can help reduce these socioeconomic burdens and improve the overall quality of life for affected women.[46-50]

Maternal Mortality

Malaria is a significant contributor to maternal mortality, particularly in malaria-endemic regions. Pregnant women are more susceptible to severe malaria due to physiological changes that affect their immune response. Severe malaria can lead to life-threatening complications such as cerebral malaria, severe anemia, and multiple organ failure, all of which increase the risk of maternal death. The World Health Organization estimates that malaria contributes to approximately 10-15% of maternal deaths in malaria-endemic regions, though this percentage can vary depending on local malaria transmission rates and healthcare conditions. Severe malaria during pregnancy can result in several critical conditions that elevate the risk of maternal mortality. These include: This severe form of malaria affects the brain and can lead to coma, seizures, and death if not promptly treated. The risk of cerebral malaria is higher in pregnant women due to their altered immune response. Malaria-induced anemia can be severe and life-threatening, leading to increased risk of postpartum hemorrhage and complications during delivery. Anemia also compromises the mother's ability to tolerate additional stress or complications. Delayed diagnosis and treatment of malaria during pregnancy can significantly increase the risk of maternal mortality. The progression from mild to severe malaria can be rapid, and delays in initiating appropriate treatment with artemisinin-based combination therapies (ACTs) can result in severe complications and increased mortality. Ensuring prompt diagnosis using rapid diagnostic tests (RDTs) and effective treatment is crucial for reducing maternal mortality. Pregnant women with pre-existing medical conditions such as hypertension, diabetes, or anemia are at an increased risk of severe outcomes when infected with malaria. The presence of these conditions can complicate the clinical management of malaria,

leading to a higher risk of maternal mortality. Integrated care approaches that address both malaria and co-existing conditions are essential for improving maternal health outcomes.[51-55]

Access to quality healthcare plays a critical role in reducing maternal mortality associated with malaria. In regions with limited healthcare infrastructure, the availability of diagnostic tools, effective treatments, and skilled healthcare providers can be inadequate. Improving healthcare access, strengthening health systems, and ensuring the availability of essential malaria interventions are key strategies for reducing maternal mortality. Socioeconomic factors, such as poverty and lack of education, influence the risk of maternal mortality from malaria. Women in lower socioeconomic settings may have limited access to preventive measures like insecticide-treated nets (ITNs) and intermittent preventive treatment (IPTp). Additionally, financial constraints and lack of transportation can delay seeking medical care, further increasing the risk of severe outcomes and mortality. Preventive measures are crucial in reducing maternal mortality associated with malaria. The use of IPTp with sulfadoxine-pyrimethamine (SP) and ITNs helps to prevent malaria infection and reduce the severity of the disease. Effective implementation of these strategies, coupled with regular antenatal care, is essential for minimizing the risk of maternal mortality. Health education plays a significant role in preventing maternal mortality from malaria. Educating pregnant women about the importance of malaria prevention, recognizing symptoms, and seeking timely medical care can help reduce the incidence of severe malaria and improve maternal outcomes. Community-based health education programs can enhance awareness and promote adherence to preventive measures.[56-60]

Effects on Pregnancy Outcomes

Malaria during pregnancy can lead to intrauterine growth restriction (IUGR), where the fetus does not grow to its full potential. This condition arises due to compromised placental function caused by malaria-induced inflammation and placental sequestration. The reduced transfer of nutrients and oxygen from the mother to the fetus impairs fetal growth, resulting in lower birth weight. IUGR is associated with increased risks of neonatal morbidity and mortality, as well as potential long-term developmental and health issues. Low birth weight (LBW) is a common outcome of malaria during pregnancy, often a direct consequence of IUGR. LBW infants are more susceptible to a range of health problems, including respiratory distress syndrome, infections, and developmental delays. Malaria-induced LBW is linked to poor neonatal outcomes and higher rates of infant mortality. Addressing malaria effectively during pregnancy is crucial for improving birth weight and overall neonatal health. Malaria is a significant risk factor for preterm birth, where the baby is born before 37 weeks of gestation. The inflammatory response triggered by malaria can lead to premature rupture of membranes, preterm labor, and other complications that result in early delivery. Preterm infants are at higher risk of complications such as respiratory distress syndrome, jaundice, and developmental delays. Preventing and managing malaria during pregnancy is essential for reducing the incidence of preterm birth and its associated risks. Stillbirth, the loss of a fetus at 20 weeks of gestation or later, can occur as a severe consequence of malaria during pregnancy. Severe malaria, particularly when complicated by placental malaria, can lead to fetal distress and intrauterine death. The risk of stillbirth is heightened by the degree of placental damage and the overall severity of the maternal malaria infection. Effective malaria prevention

and treatment strategies are vital for reducing the risk of stillbirth and ensuring better pregnancy outcomes.[61-65]

Neonatal mortality, the death of a newborn within the first 28 days of life, can be increased due to complications associated with malaria during pregnancy. Infants born to mothers with malaria are at higher risk of experiencing complications such as infections, respiratory distress, and low birth weight, all of which contribute to increased neonatal mortality. Ensuring effective malaria control during pregnancy is crucial for improving neonatal survival rates and overall infant health. Complications associated with malaria during pregnancy, such as severe illness and prolonged hospital stays, can impact maternal-fetal bonding. The stress and physical burden of dealing with malaria can affect a mother's emotional well-being and her ability to engage in early bonding with her infant. Addressing malaria effectively and providing support for maternal health can help improve maternal-fetal bonding and overall family well-being. Children born to mothers with malaria during pregnancy may experience long-term developmental effects. These can include cognitive and motor delays, learning disabilities, and behavioral issues. The impact of malaria on fetal development, particularly in cases of severe infection or IUGR, can have lasting implications for a child's health and development. Early interventions and follow-up care are important for addressing and managing any developmental concerns. The effects of malaria during pregnancy can also impact maternal health in the postpartum period. Severe malaria can lead to complications such as anemia, fatigue, and weakened immune function, which may affect recovery and overall health after childbirth. Ensuring appropriate postpartum care and management is essential for supporting maternal recovery and addressing any health issues related to malaria. The adverse pregnancy outcomes associated with malaria can have broader socioeconomic implications. Low birth weight, preterm birth, and stillbirth can lead to increased healthcare costs, long-term developmental needs, and potential loss of productivity for families. Addressing malaria and improving pregnancy outcomes can help reduce these socioeconomic burdens and enhance the quality of life for affected families.[66-70]

Intermittent Preventive Treatment (IPTp)

Intermittent Preventive Treatment in Pregnancy (IPTp) is a malaria control strategy designed to reduce the incidence of malaria and its associated complications among pregnant women. IPTp involves administering antimalarial medication at scheduled intervals, regardless of whether the patient is symptomatic or asymptomatic. The primary goals of IPTp are to prevent malaria infection, reduce the risk of severe malaria and its complications, and improve overall pregnancy outcomes. This approach is particularly crucial in malaria-endemic regions where the burden of disease is high and where pregnant women are at increased risk. The most commonly used drug for IPTp is sulfadoxine-pyrimethamine (SP). SP is chosen due to its effectiveness in clearing malaria parasites and its relatively long half-life, which allows for effective prophylaxis with fewer doses. The WHO recommends administering IPTp with SP at each scheduled antenatal visit, starting from the second trimester (usually after 13 weeks of gestation) and continuing at monthly intervals until delivery. The frequency and timing of administration may vary based on local

guidelines and drug availability. SP works by inhibiting the synthesis of folate, an essential nutrient for the malaria parasite. By disrupting folate metabolism, SP effectively reduces parasite proliferation and clears existing infections. During pregnancy, IPTp with SP helps prevent the establishment of new infections and reduces the severity of malaria, thereby protecting both the mother and the fetus. The drug's long-acting properties ensure sustained protection against malaria during critical periods of pregnancy. Clinical studies have demonstrated that IPTp with SP significantly reduces the incidence of malaria during pregnancy, as well as associated complications such as severe anemia, low birth weight, and preterm birth. IPTp has been shown to decrease maternal and fetal morbidity and mortality by providing a protective effect against malaria throughout pregnancy. Implementation of IPTp programs has contributed to substantial reductions in malaria-related adverse outcomes in several malaria-endemic regions.[71-75]

The effectiveness of IPTp is closely linked to its coverage and proper implementation. Factors influencing coverage include healthcare infrastructure, availability of medications, and accessibility to antenatal care services. Efforts to improve IPTp coverage involve increasing awareness among pregnant women, ensuring the availability of SP, and strengthening healthcare delivery systems. Challenges such as drug resistance and supply chain issues can impact the success of IPTp programs, highlighting the need for continuous monitoring and adaptation. IPTp with SP is generally considered safe for use during pregnancy. The drug has a well-established safety profile and is associated with minimal side effects. However, like any medication, it may cause adverse reactions in some individuals, such as gastrointestinal discomfort or allergic reactions. Monitoring and managing potential side effects are important to ensure patient safety and adherence to the treatment regimen. The emergence of drug-resistant strains of malaria parasites poses a challenge to the effectiveness of IPTp. Resistance to SP has been reported in some regions, which can reduce the efficacy of the treatment and complicate malaria control efforts. Surveillance of drug resistance and the development of alternative treatment options are crucial for maintaining the effectiveness of IPTp and ensuring continued protection for pregnant women. IPTp is most effective when integrated with other malaria control strategies, such as the use of insecticide-treated nets (ITNs) and indoor residual spraying (IRS). Combining IPTp with these preventive measures provides a comprehensive approach to malaria control and enhances overall effectiveness. Integrated malaria control programs that include IPTp, ITNs, and IRS can significantly reduce the burden of malaria and improve pregnancy outcomes. Global and national health policies play a critical role in the implementation of IPTp programs. The World Health Organization (WHO) provides guidelines and recommendations for IPTp, which are adapted and implemented by national health authorities. Adherence to these guidelines ensures the standardized delivery of IPTp and helps address local challenges and variations in malaria transmission and healthcare infrastructure.[76-80]

Insecticide-Treated Nets (ITNs)

Insecticide-Treated Nets (ITNs) are a cornerstone of malaria prevention strategies, especially in endemic regions. ITNs are bed nets that have been treated with insecticides to repel or kill mosquitoes that come into contact with them. The primary purpose of ITNs is to provide a barrier between the sleeping individual and malaria-carrying mosquitoes, thereby reducing the risk of

malaria transmission. By preventing mosquito bites, ITNs help decrease the incidence of malaria, particularly among vulnerable populations such as pregnant women and young children. There are two main types of ITNs: long-lasting insecticidal nets (LLINs) and conventional ITNs. LLINs are treated with insecticides that remain effective for several years, even after repeated washing. They are designed to provide long-term protection and are preferred due to their durability and sustained efficacy. Conventional ITNs, on the other hand, require re-treatment with insecticides after a certain period or after several washes to maintain their effectiveness. ITNs function through a dual mechanism: they repel mosquitoes and kill them upon contact. The insecticides used in ITNs, such as permethrin or deltamethrin, are effective at disrupting the nervous system of mosquitoes, leading to their death. By reducing the mosquito population in and around sleeping areas, ITNs significantly lower the chances of malaria transmission. The protective effect extends to other individuals in the household who may not be using the net directly but are still within the vicinity of the treated net. The use of ITNs has been shown to substantially reduce malaria incidence and mortality rates in endemic regions. Studies have demonstrated that ITNs can decrease the number of clinical malaria cases by up to 50% and reduce all-cause mortality among young children by approximately 20%. The widespread distribution and use of ITNs have been associated with significant declines in malaria prevalence and have contributed to the global reduction in malaria cases.[81-85]

Effective implementation of ITNs involves several key steps: distribution, education, and maintenance. ITNs are often distributed through mass campaigns or integrated into antenatal care services. Education on the proper use and care of ITNs is essential to maximize their effectiveness. Regular monitoring and evaluation of ITN coverage and use are crucial for identifying gaps and ensuring that the nets are reaching those most in need. Despite their effectiveness, ITNs face several challenges. Issues such as inadequate coverage, improper use, and maintenance can reduce their impact. For example, nets may be used for purposes other than sleeping, such as fishing or farming, which compromises their effectiveness. Additionally, the emergence of insecticide-resistant mosquito strains can diminish the efficacy of ITNs. Addressing these challenges requires ongoing efforts to improve distribution systems, educate users, and monitor resistance patterns. Insecticide resistance is a growing concern that affects the efficacy of ITNs. Over time, mosquito populations may develop resistance to the insecticides used in ITNs, reducing their effectiveness in killing or repelling mosquitoes. Monitoring and managing insecticide resistance through the use of different insecticides, rotating insecticides, and employing alternative vector control measures are essential for maintaining the effectiveness of ITNs. ITNs are most effective when used in combination with other malaria control measures, such as Intermittent Preventive Treatment in Pregnancy (IPTp) and indoor residual spraying (IRS). Integrating ITNs with these strategies provides a comprehensive approach to malaria prevention, addressing different aspects of malaria transmission and improving overall control efforts. Global and national policies and guidelines play a crucial role in the promotion and distribution of ITNs. The World Health Organization (WHO) and other health authorities provide recommendations on ITN use, distribution, and maintenance. Adherence to these guidelines ensures that ITNs are used effectively and that malaria prevention efforts are standardized and evidence-based.[86-89]

Prompt Diagnosis and Treatment

Prompt and accurate diagnosis of malaria is critical for effective treatment and reducing the risk of severe complications. Early detection of malaria allows for the timely initiation of treatment, which is essential for preventing the progression of the disease from mild to severe forms. Early diagnosis helps reduce the burden on healthcare systems, minimizes transmission, and improves overall patient outcomes. In pregnancy, early diagnosis is particularly important as malaria can have serious implications for both maternal and fetal health. Artemisinin-Based Combination Therapies (ACTs) are the first-line treatment for uncomplicated malaria. They combine artemisinin derivatives with another antimalarial drug to enhance efficacy and prevent resistance. Common ACTs include artemether-lumefantrine and artesunate-amodiaquine. Chloroquine **u**sed primarily for Plasmodium vivax and Plasmodium ovale infections, chloroquine is effective in clearing parasites but is not recommended for multidrug-resistant strains. Quinine is used for treating severe malaria or when ACTs are contraindicated. It is usually administered in combination with other antimalarial drugs. For severe cases of malaria, such as cerebral malaria or severe anemia, intravenous administration of artesunate or quinine is required. Supportive care, including hydration, blood transfusion, and management of complications, is also essential. Pregnant women require special consideration when treating malaria due to the potential impact on both the mother and the fetus. The recommended treatment for uncomplicated malaria in pregnancy is generally ACTs, with artemether-lumefantrine being the preferred choice. For severe malaria in pregnant women, intravenous artesunate is the recommended treatment. Safe and effective management of malaria in pregnancy requires careful balancing of drug efficacy and safety to minimize risks to both the mother and the fetus. Prompt diagnosis and treatment are most effective when integrated with other malaria control measures, such as preventive treatments, vector control, and health education. Combining these strategies helps to address different aspects of malaria transmission and enhances overall control efforts. Regular monitoring and evaluation of diagnostic and treatment practices are essential for ensuring effectiveness and identifying areas for improvement. Surveillance systems should be in place to track treatment outcomes, monitor drug resistance, and assess the impact of interventions on malaria incidence and severity. Training healthcare workers in accurate diagnosis and effective treatment of malaria is crucial for improving patient outcomes. Capacity building includes enhancing skills in microscopy, RDT interpretation, and treatment protocols, as well as ensuring ongoing education about emerging challenges and best practices.[70-75]

Health Education and Behavioral Change

Health education plays a critical role in malaria prevention and control by increasing awareness and knowledge about the disease, its transmission, and preventive measures. Effective health education empowers individuals and communities to make informed decisions and adopt behaviors that reduce the risk of malaria. It involves disseminating accurate information through various channels, such as community meetings, health campaigns, and educational materials, to promote understanding and encourage preventive practices. Health education is instrumental in promoting

the use of preventive measures such as insecticide-treated nets (ITNs), intermittent preventive treatment in pregnancy (IPTp), and indoor residual spraying (IRS). Educating individuals about the proper use and benefits of ITNs, including how to hang and maintain them, helps increase their adoption and effectiveness. Similarly, informing pregnant women about the importance of IPTp and ensuring they adhere to treatment schedules can significantly reduce malaria risk during pregnancy. Behavior Change Communication (BCC) is a strategic approach that combines communication and behavioral theory to encourage individuals to adopt healthy behaviors. Crafting messages that resonate with the target audience's values and concerns, highlighting the benefits of adopting preventive measures and addressing barriers to behavior change. Involving community leaders and influencers to promote malaria prevention and treatment practices, leveraging their authority and trust within the community to drive change. Utilizing interactive methods such as role-playing, discussions, and demonstrations to engage individuals and reinforce key messages about malaria prevention and control. Limited knowledge about malaria transmission and prevention can hinder the adoption of protective measures. Education efforts should focus on increasing awareness and understanding. The cost of purchasing ITNs or accessing healthcare services can be a barrier for some individuals. Programs that provide free or subsidized ITNs and support for accessing healthcare can help overcome financial barriers. Cultural beliefs and practices may influence attitudes toward malaria prevention and treatment. Health education should be culturally sensitive and address misconceptions or misinformation about malaria.[76-80]

Improving health literacy is crucial for enabling individuals to understand health information and make informed decisions. Health education programs should focus on enhancing health literacy by using clear and simple language, providing visual aids, and ensuring that information is accessible to individuals with varying levels of education. Effective health literacy can lead to better adherence to preventive measures and treatment recommendations. Community-based interventions are effective in reaching diverse populations and addressing local needs. Engaging community members in health education activities, such as peer education programs and community health worker training, helps build local capacity and fosters a sense of ownership and responsibility for malaria prevention. Community-based approaches also facilitate the dissemination of information through trusted channels and networks. Evaluating the impact of health education and behavioral change initiatives is essential for assessing effectiveness and identifying areas for improvement. Monitoring and evaluation should include assessing changes in knowledge, attitudes, and practices related to malaria prevention and treatment. Feedback from the community can help refine strategies and ensure that interventions are responsive to local needs. Integrating health education into routine healthcare services enhances the reach and impact of malaria prevention and control efforts. Healthcare providers should incorporate educational components into patient interactions, such as discussing malaria prevention strategies during antenatal care visits or counseling patients on the importance of completing antimalarial treatments. This integration ensures that health education is part of comprehensive care and reinforces key messages. Technology and media can be powerful tools for disseminating health information and promoting behavioral change. Using platforms such as social media, mobile health applications, and radio or television broadcasts can expand the reach of health education efforts and engage a broader audience. Tailoring messages for different media channels and

leveraging technology for interactive and engaging content can enhance the effectiveness of health education campaigns.[85-89]

Conclusion

Health education and behavioral change are pivotal in the fight against malaria, serving as essential components in malaria prevention and control strategies. By increasing awareness and understanding of malaria transmission and prevention, health education empowers individuals and communities to adopt effective preventive measures such as using insecticide-treated nets (ITNs), adhering to intermittent preventive treatment in pregnancy (IPTp), and seeking prompt diagnosis and treatment. Behavior Change Communication (BCC) strategies, which focus on motivating and engaging individuals, addressing barriers, and enhancing health literacy, play a crucial role in shifting attitudes and practices related to malaria. Community-based interventions and the integration of health education into healthcare services further amplify the reach and effectiveness of these efforts.

References

1. Uneke CJ. Impact of placental Plasmodium falciparum malaria on pregnancy and perinatal outcome in sub-Saharan Africa: part III: placental malaria, maternal health, and public health. The Yale journal of biology and medicine. 2008;81(1):1.
2. Gontie GB, Wolde HF, Baraki AG. Prevalence and associated factors of malaria among pregnant women in Sherkole district, Benishangul Gumuz regional state, West Ethiopia. BMC Infectious Diseases. 2020; 20:1-8.
3. Obeagu EI, Agreen FC. Anaemia among pregnant women: A review of African pregnant teenagers. J Pub Health Nutri. 2023; 6 (1). 2023;138. links/63da799664fc860638054562/Anaemia-among-pregnant-women-A-review-of-African-pregnant-teenagers.pdf.
4. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-8. links/5710fae108ae846f4ef05afb/ERYTHROPOIETIN-IN-THE-ANAEMIAS-OF-PREGNANCY-A-REVIEW.pdf.
5. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. J Res Med Dent Sci. 2021;9(4):145-8. links/608a6728a6fdccaebdf52d94/Assessment-of-Haematological-Changes-in-Pregnant-Women-of-Ido-Ondo.pdf.
6. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 ;6(2):10-3. http://irmhs.com/index.php/irmhs/article/view/111.
7. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.

8. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. Madonna University journal of Medicine and Health Sciences. 2022;2(2):1-9.
9. Bonilla FA, Oettgen HC. Adaptive immunity. Journal of Allergy and Clinical Immunology. 2010;125(2): S33-40.
10. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. EVALUATION OF PROTEIN C, PROTEIN S AND FIBRINOGEN OF PREGNANT WOMEN WITH MALARIA IN OWERRI METROPOLIS. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(2):1-9.
11. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.
12. Feeney ME. The immune response to malaria in utero. Immunological reviews. 2020 ;293(1):216-229.
13. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine. 2023;102(46): e36166.
14. Obeagu EI, Chijioke UO, Ekelozie IS. Malaria rapid diagnostic test (RDTs). Ann Clin Lab Res. 2018;6(4):275.
15. Ogomaka IA, Obeagu EI. Methods of Breast Feeding as Determinants of Malaria Infections among Babies in IMO State, Nigeria. International Journal of Medical Science and Dental Research. 2019;2(01):17-24.
16. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. Evaluation of protein C, protein S and fibrinogen of pregnant women in Owerri Metropolis. Madonna University Journal of Medicine and Health Sciences. 2022;2(1):292-8. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/57.
17. Obeagu EI, Obeagu GU, Adepoju OJ. Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. J. Bio. Innov11 (3). 2022:936-941.
18. Obeagu EI, Obeagu GU, Egba SI, Emeka-Obi OR. Combatting Anemia in Pediatric Malaria: Effective Management Strategies. Int. J. Curr. Res. Med. Sci. 2023;9(11):1-7.
19. Hassan AO, Oso OV, Obeagu EI, Adeyemo AT. Malaria Vaccine: Prospects and Challenges. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022;2(2):22-40.
20. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-9.
21. Moya-Alvarez V, Abellana R, Cot M. Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. Malaria journal. 2014; 13:1-10.
22. Obeagu EI. An update on utilization of antenatal care among pregnant Women in Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(9): 21-6.DOI: 10.22192/ijcrcps.2022.09.09.003
23. Okoroiwu IL, Obeagu EI, Obeagu GU. Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri, Nigeria. Madonna

University Journal of Medicine and Health Sciences. 2022;2(2):91-97. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/67.

24. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ. Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State. Nigeria. Journal of Research in Medical and Dental Science. 2021;9(12):462-.links/61b1e32f0c4bfb675178bfa7/Evaluation-of-Changes-in-Haematological-Parameters-of-Pregnant-Women-Based-on-Gestational-Age-at-Olorunsogo-Road-Area-of-Ido-Ondo-State-Nigeria.pdf.
25. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022 Jun 21;5(2):113-121.
26. Obeagu EI. Gestational Thrombocytopaenia. J Gynecol Women's Health. 2023;25(3):556163. links/64b01aa88de7ed28ba95fccb/Gestational-Thrombocytopaenia.pdf.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
28. Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM. High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal. 2018; 17:1-3.
29. Obeagu EI, Busari AI, Uduchi IO, Ogomaka IA, Ibekwe AM, Vincent CC, Chijioke UO, Okafor CJ, Okoroiwu HU, Adike CN. Age-Related Haematological Variations in Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):218-24.
30. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
31. Ogbonna CO, Obeagu EI, Ufelle SA, Ogbonna LN. Evaluation of haematological alterations in children infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(1):38-45.
32. Appay V. The physiological role of cytotoxic CD4+ T-cells: the holy grail? Clinical & Experimental Immunology. 2004;138(1):10-13.
33. Okorie HM, Obeagu EI, Obarezi HC, Anyiam AF. Assessment of some inflammatory cytokines in malaria infected pregnant women in Imo State Nigeria. International Journal of Medical Science and Dental Research. 2019;2(1):25-36.
34. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9):1-4.
35. Nwosu DC, Obeagu EI, Ezenwuba C, Agu GC, Amah H, Ozims SJ, Nwanjo HU, Edward A, Izuchukwu IF, Amadike JN, Nwagwu AJ. Antioxidant status of children with Plasmodium falciparum malaria in Owerri municipal council of Imo state. Int. J. Curr. Res. Chem. Pharm. Sci. 2016;3(8):40-46.

36. Harrington WE, Kakuru A, Jagannathan P. Malaria in pregnancy shapes the development of foetal and infant immunity. Parasite immunology. 2019;41(3): e12573.
37. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. Annals of Clinical and Laboratory Research. 2017;5(4):206.
38. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Irondi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. Asian Hematology Research Journal. 2022;6(3):9-17.
39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15.
40. Offie DC, Ibekwe AM, Agu CC, Esimai BN, Okpala PU, Obeagu EI, Ufelle SA, Ogbonna LN. Fibrinogen and C-Reactive Protein Significance in Children Infected by Plasmodium falciparum Species in Enugu, Enugu State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(15):1-8.
41. Obeagu EI, Ogunnaya FU. PREGNANCYINDUCED HAEMATOLOGICAL CHANGES: A KEY TO MARTERNAL AND CHILD HEALTH. European Journal of Biomedical. 2023;10(8):42-43. links/64c890bddb38b20d6dad2c5c/PREGNANCY-INDUCED-HAEMATOLOGICAL-CHANGES-A-KEY-TO-MARTERNAL-AND-CHILD-HEALTH.pdf
42. Obeagu EI, Ofodile AC, Okwuanaso CB. A review of urinary tract infections in pregnant women: Risks factors. J Pub Health Nutri. 2023; 6 (1). 2023; 137:26-35. links/63c3a9116fe15d6a571e8bba/A-review-of-urinary-tract-infections-in-pregnant-women-Risks-factors.pdf.
43. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2): 14-17.DOI: 10.22192/ijcrms.2023.09.02.003
44. Obeagu EI, Obeagu GU, Ogunnaya FU. Deep vein thrombosis in pregnancy: A review of prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 14-21.DOI: 10.22192/ijcrcps.2023.10.08.002
45. Arama C, Quin JE, Kouriba B, Östlund Farrants AK, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. Frontiers in Immunology. 2018; 9:1733.
46. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. Int. J. Curr. Res. Biol. Med. 2018;3(9): 1-4.DOI: 10.22192/ijcrbm.2018.03.09.001
47. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF. Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. Int J Curr Res Biol Med. 2017;2(2): 13-23.DOI: 10.22192/ijcrbm.2017.02.02.003
48. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, Ibekwe AM, Amaechi CO, Agu CC, Anoh NV, Amadi NM. Evaluation of Iron Status, Haemoglobin

and Protein Levels of Pregnant Women in Owerri Metropolis. Journal of Pharmaceutical Research International. 2021;33(27A):36-43.
49. Obeagu EI, Njar VE, Obeagu GU. Infertility: Prevalence and Consequences. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(7):43-50.
50. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
51. Broen K, Brustoski K, Engelmann I, Luty AJ. Placental Plasmodium falciparum infection: causes and consequences of in utero sensitization to parasite antigens. Molecular and biochemical parasitology. 2007;151(1):1-8.
52. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9):41-49.
53. Ogbonna LN, Ezeoru VC, Ofodile AC, Ochiabuto OM, Obi-Ezeani CN, Okpala PU, Okafor CJ, Obeagu GU, Busari AI, Obeagu EI. Gender Based Variations of Haematological Parameters of Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(8):75-80.
54. Eberendu IF, Ozims SJ, Agu GC, Amah HC, Obasi CC, Obioma-Elemba JE, Ihekaire DE, Ibanga IE, Amah CC, Obeagu EI, Nwosu DC. Impact of human activities on the breeding of mosquitoes of human disease in Owerri metropolis, Imo state. Int J Adv Res Biol Sci IJARBS. 2017;4(12):98-106.
55. Obeagu EI, Ofodile AC, Okwuanaso CB. A review on socio economic and behavioral aspects of malaria and its control among children under 5 years of age in Africa. J Pub Health Nutri. 2023; 6 (1): 136.
56. Djontu JC, Siewe Siewe S, Mpeke Edene YD, Nana BC, Chomga Foko EV, Bigoga JD, Leke RF, Megnekou R. Impact of placental Plasmodium falciparum malaria infection on the Cameroonian maternal and neonate's plasma levels of some cytokines known to regulate T cells differentiation and function. Malaria journal. 2016; 15:1-1.
57. Obeagu EI, Faduma MH, Uzoma G. Ectopic Pregnancy: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4): 40-4.DOI: 10.22192/ijcrcps.2023.10.04.004
58. Obeagu EI, Gamade SM, Obeagu GU. The roles of Neutrophils in pregnancy. Int. J. Curr. Res. Med. Sci. 2023;9(5): 31-35.DOI: 10.22192/ijcrms.2023.09.05.005
59. Obeagu EI, Obeagu GU. Molar Pregnancy: Update of prevalence and risk factors. Int. J. Curr. Res. Med. Sci. 2023;9(7): 25-28.DOI: 10.22192/ijcrms.2023.09.07.005
60. Kabyemela E, Gonçalves BP, Prevots DR, Morrison R, Harrington W, Gwamaka M, Kurtis JD, Fried M, Duffy PE. Cytokine profiles at birth predict malaria severity during infancy. PloS one. 2013;8(10):e77214.
61. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state, Nigeria. International Journal of Advanced Multidisciplinary Research. 2017;4(8): 1-9.DOI: 10.22192/ijamr.2017.04.08.001
62. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies

Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.

63. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. International Journal of Current Research in Medical Sciences. 2018;4(9): 41-9.DOI: 10.22192/ijcrms.2018.04.09.006
64. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8): 22-6.DOI: 10.22192/ijcrcps.2023.10.08.003
65. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. ZINC LEVEL IN APPARENTLY PREGNANT WOMEN IN URBAN AREA. Madonna University journal of Medicine and Health Sciences. 2022;2(1):134-48. https://www.journal.madonnauniversity.edu.ng/index.php/medicine/article/view/40.
66. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(41B):380-386.
67. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. SICKLE CELL ANAEMIA: A GESTATIONAL ENIGMA. migration. 2023; 17:18.
68. Harrington WE, Kakuru A, Jagannathan P. Malaria in pregnancy shapes the development of foetal and infant immunity. Parasite immunology. 2019;41(3):e12573.
69. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4. https://www.academia.edu/download/56538560/A_Review_on_Erythropietin_in_Pregnancy.pdf.
70. Ifeanyi OE. A review on pregnancy and haematology. Int. J. Curr. Res. Biol. Med. 2018;3(5): 26-8.DOI: 10.22192/ijcrbm.2018.03.05.006
71. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuike JE, Ezeama MC. Ihekireh. Changes in liver enzymes and lipid profile of pregnant women with malaria in Owerri, Nigeria. International Journal of Current Research and Academic Review. 2015;3(5):376-383.
72. Ibebuike JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, Nwanjo HU, Agu GC, Ezenwuba CO, Nwagu SA, Akujuobi AU. Factors that influence women's utilization of primary health care services in Calabar Cros river state, Nigeria. Int. J. Curr. Res. Chem. Pharm. Sci. 2017;4(7):28-33.
73. Elemchukwu Q, Obeagu EI, Ochei KC. Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. IOSR Journal of Pharmacy and Biological Sciences. 2014;9(5):59-64.
74. Natama HM, Moncunill G, Rovira-Vallbona E, Sanz H, Sorgho H, Aguilar R, Coulibaly-Traoré M, Somé MA, Scott S, Valéa I, Mens PF. Modulation of innate immune responses at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC medicine. 2018; 16:1-5.
75. Akandinda M, Obeagu EI, Katonera MT. Non Governmental Organizations and Women's Health Empowerment in Uganda: A Review. Asian Research Journal of Gynaecology and Obstetrics. 2022;8(3):12-26.

76. Gamde MS, Obeagu EI. IRON DEFICIENCY ANAEMIA: ENEMICAL TO PREGNANCY. European Journal of Biomedical. 2023;10(9):272-275. links/64f63358827074313ffaae7b/IRON-DEFICIENCY-ANAEMIA-ENEMICAL-TO-PREGNANCY.pdf.
77. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. Journal of Pharmaceutical Research International. 2021;33(42A):53-65.
78. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM. Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021;33(42B):39-48.
79. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-26.
80. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023;6(2):10-13.
81. Mutabingwa TK, Bolla MC, Li JL, Domingo GJ, Li X, Fried M, Duffy PE. Maternal malaria and gravidity interact to modify infant susceptibility to malaria. PLoS medicine. 2005;2(12):e407.
82. Gamble C, Ekwaru PJ, Garner P, Ter Kuile FO. Insecticide-treated nets for the prevention of malaria in pregnancy: a systematic review of randomised controlled trials. PLoS medicine. 2007;4(3):e107.
83. Okoko BJ, Enwere G, Ota MO. The epidemiology and consequences of maternal malaria: a review of immunological basis. Acta tropica. 2003;87(2):193-205.
84. Dobaño C, Berthoud T, Manaca MN, Nhabomba A, Guinovart C, Aguilar R, Barbosa A, Groves P, Rodríguez MH, Jimenez A, Quimice LM. High production of pro-inflammatory cytokines by maternal blood mononuclear cells is associated with reduced maternal malaria but increased cord blood infection. Malaria Journal. 2018; 17:1-3.
85. Umbers AJ, Stanisic DI, Ome M, Wangnapi R, Hanieh S, Unger HW, Robinson LJ, Lufele E, Baiwog F, Siba PM, King CL. Does malaria affect placental development? Evidence from in vitro models. PLoS One. 2013;8(1):e55269.
86. Arama C, Quin JE, Kouriba B, Östlund Farrants AK, Troye-Blomberg M, Doumbo OK. Epigenetics and malaria susceptibility/protection: A missing piece of the puzzle. Frontiers in Immunology. 2018; 9:1733.
87. Gbedande K, Carpio VH, Stephens R. Using two phases of the CD 4 T cell response to blood-stage murine malaria to understand regulation of systemic immunity and placental pathology in Plasmodium falciparum infection. Immunological reviews. 2020;293(1):88-114.
88. Lindsay SW, Thomas MB, Kleinschmidt I. Threats to the effectiveness of insecticide-treated bednets for malaria control: thinking beyond insecticide resistance. The Lancet Global Health. 2021;9(9): e1325-1331.
89. Akinleye SO, Falade CO, Ajayi IO. Knowledge and utilization of intermittent preventive treatment for malaria among pregnant women attending antenatal clinics in primary health care centers in rural southwest, Nigeria: a cross-sectional study. BMC pregnancy and childbirth. 2009; 9:1-9.